StemCell Therapy

Precision Medicine Market Size was valued around USD 50 billion in 2018 and is expected to witness lucrative growth from 2019 to 2025.

Rising demand and advancements in cancer biology will augment personalized medicine market during the forecast timeframe. Development of novel genetic technologies that discovers the functional effect of genetic information that leads in developing cancer, thus, should propel huge demand for cancer biology. However, the high price associated with usage of precision medicine may restrict the precision medicine market growth over forecast period.

Download the sample report to understand the market growth in Precision Medicine Market:

https://www.insidemarketreports.com/sample-request/9/137670/precision-medicine-markets

On the basis of technology the precision medicine market is segregated into big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics. Rising focus of competitors on producing advanced drugs leading to better treatment for several chronic diseases will drive drug discovery segmental growth. Similarly, rising incidence of chronic as well as respiratory diseases will drive the growth of the market.

Precision medicine market by application is further divided into oncology, immunology, central nervous system (CNS), respiratory diseases. Increasing prevalence of cancer cases and usage of precision medicine in development of new drugs will increase the oncology segmental market growth. Similarly, increasing demand for bioinformatics and big data analytics to set apart human genome data secured from immunological processes augment segmental growth.

On the basis of end users, the precision medicine market is further divided as pharmaceutical companies, diagnostic companies, healthcare IT companies. Rising demand for producing novel tools for rapid integration, storage, and analysis of patient information will drive the business growth.

North America is anticipated to account for the largest share of the Global Precision Medicine Market. Increasing prevalence of cancer across the U.S will augment the growth of the precision medicine market. Similarly, rising healthcare expenditure will drive the growth of precision medicine market over the forecast period. Asia-Pacific is expected to show rapid growth in coming years owing to growing number of investments in R&D activities.

By Technology

By Application

By End users

By Region

Company Coverage

Conclusion:

In this report, we had discussed the market situation of Precision Medicine Market. As we know the world is going to be tech savvy, the demand of trending products and technologies is also increasing. This report can help to understand the business growth in the Precision Medicine Market and new opportunities at new places.

The only person you are destined to become is the person you decide to be!!

Hurry up! and grab the discount for this report

https://www.insidemarketreports.com/discount/9/137670/precision-medicine-markets

For any type of research report, Contact us at:

Company Name: Inside Market Reports

Address: 1 Apache Way, Westford, Massachusetts 01886, USA

Email: [emailprotected]

Contact no: +1-617-230-0741

Go here to read the rest:
Global Precision Medicine Market Growth From 2019 to 2025- Market Report, Insights Analysis And Opportunities - Cole of Duty

REDMOND, Wash. June 18, 2020 On Thursday, Microsoft Corp. and Johns Hopkins Medicine (JHM) announced a five-year relationship centered on Microsofts Azure and analytical tools that will support new discoveries as part of JHMs inHealth precision medicine initiative. The work will bring together JHMs leading global research expertise with the power of Microsoft Azure, and its AI capabilities, to help advance JHMs discoveries that will benefit personalized health care. JHM will maintain total control over its data.

inHealth embodies Johns Hopkins commitment to precision medicine, using new tools to understand and manage patients health, informed by their broader health history and environment. This program integrates JHMs longstanding leadership in health care research and delivery with the expertise of the Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Whiting School of Engineering and Johns Hopkins University Applied Physics Lab.

In support of inHealth, JHM has established 16 Precision Medicine Centers of Excellence, where researchers are pursuing breakthroughs in numerous disease settings, such as prostate cancer and multiple sclerosis. JHM aims to have 50 centers in the next five years.

Ad StatisticsTimes Displayed: 1049244Times Visited: 9191

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Ethical use of patient data is a cornerstone of all of JHMs partnerships with patients, including this important work with Microsoft in precision medicine. All projects are compliant with all appropriate privacy regulations, and JHM maintains strict control over all data, including through the use of its Institutional Review Board and its internal Data Trust Council that reviews data use across JHM.

It is a distinct privilege to partner with many of the worlds leading physicians, scientists and engineers at JHM as they use Microsoft Azure and its AI and machine learning capabilities to support some of the most advanced research and breakthroughs in precision medicine, said Gregory Moore, M.D., Ph.D., corporate vice president of Microsoft Health. Im inspired by the collaboration and its bold goals to improve health for all by bringing together some of the worlds best minds in medicine and technology to deliver the future of medical science innovation.

JHM has previously used Microsoft services as JHM developed its pioneering Precision Medicine Analytics Platform (PMAP), a highly innovative data platform that allows collection and analysis information from a broad array of sources in a secure environment. This new agreement will enable inHealth to expand use of other Microsoft resources, such as advanced services, AI, machine learning and analytics.

More information about Johns Hopkins Medicine precision medicine work and inHealth can be found here.

Microsoft (Nasdaq MSFT @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

More here:
Microsoft Azure will become the preferred cloud platform for Johns Hopkins in Health precision medicine initiative - DOTmed HealthCare Business News

By Kevin Brown

Precision radiation medicine is a twenty-first century approach to fundamental cancer therapy. Approximately 50-60 percent of cancer patients will receive radiation therapy at some point during their cancer journey, as it is used for curative regimens and palliative care. Radiation therapy has been a pillar of cancer treatment for most of the past century, yet far from being an old or unsophisticated technology, recent advances in radiation delivery technology and software automation have enabled a new era of personalized precision radiation medicine.

The ability to develop personalized radiation therapy regimens is a direct result of the increased precision and accuracy with which cutting-edge systems deliver radiation doses. These systems enable delivery of higher doses of radiation to tumors, which increases efficacy, while reducing exposure of normal tissue, which is essential for improving safety, tolerability and long-term toxicity. The improved targeting to tumors allows more radiation to be delivered during each treatment session, which results in fewer sessions, reduces patients treatment burden, and allows more patients to be treated on each delivery system. Importantly, improved targeting is also opening the door to the use of radiation therapy in hard-to-treat cancers that are not amenable to traditional radiation therapy approaches.

Ad StatisticsTimes Displayed: 1049244Times Visited: 9191

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

The challenges of cancer care during the Covid-19 pandemicThe Covid-19 pandemic presents unique and diverse challenges to the safe and effective delivery of cancer care. A key challenge is that many cancer therapies, including chemotherapy and some targeted therapies, are immunosuppressive. Patients treated with these therapies have an increased risk of infection in routine treatment, and these regimens put patients at high risk of infection with SARS-CoV-2, the virus that causes Covid-19. The curtailing of non-emergency surgeries at most hospitals and cancer care centers is also upending standard of care cancer regimens that include surgery.

Link:
Precision radiation medicine and Covid-19: Providing optimal outcomes during extraordinary times - DOTmed HealthCare Business News

NEW YORK, June 18, 2020 /PRNewswire/ --

INTRODUCTIONHarnessing the naturally evolved, medicinal functions of gut bacteria in order to achieve desired clinical outcomes / bene?ts is the core principle behind the rapidly growing field of microbiome therapeutics. In fact, in recent years, promising insights from microbiome focused research has been the cause of much enthusiasm within the medical science community, offering a novel perspective related to personalized medicine. , This particular class of products exists at the interface of naturopathic remedies (considering the active substances that are currently used) and clinically validated interventions, having demonstrated the ability to offer legitimate, quantifiable clinical benefits. Around 200 companies, including both private and public stakeholders, claim to be currently engaged in developing microbiome-based therapies for the treatment of a wide range of diseases. Several large pharmaceutical companies have also demonstrated interest in partnering with early-stage innovators in this domain. , Having said that, most such initiatives are either still in the preclinical stages or early phase clinical trials. There are a few microbiome-based product candidates in phase II/III trials, which are anticipated to drive the market's growth in the short-mid term. According to our estimates, the microbiome-based therapeutics market is projected to be worth over USD 1.5 billion by 2030, growing at an annualized rate of over 30%.

Read the full report: https://www.reportlinker.com/p05915359/?utm_source=PRN

Despite the evident increase in interest in this field, manufacturing live microbial therapeutics remains a largely unaddressed area of concern. In fact, experts believe that the lack of sufficient manufacturing capacity is one of the major impediments to the commercialization of such products. Other challenges include absence of the required industry standards related to manufacturing live biotherapeutics, reproducibility (batch-to-batch consistency) related concerns, lack of expertise and infrastructure to handle anaerobic microbial strains, scaling up existing manufacturing protocols, intellectual property related issues (existing patent law prohibits patenting live organisms and naturally occurring materials) and uncertainties related to regulatory review and product approval. Owing to the aforementioned reasons and several others, such as need for specialized facilities, equipment and operational expertise, innovator companies have begun relying on contract manufacturers for their microbiome-related development and production needs. Outsourcing is known to offer several benefits, which include reductions in capital investment, access to larger production capacities, expediting time-to-market, and commercial risk handling and mitigation (to a significant extent). Presently, a number of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) claim to offer services for manufacturing microbiome-related products. In fact, some have even developed end-to-end capabilities, starting from drug development to regulatory filings, and commercial scale production, in this field.

SCOPE OF THE REPORTThe "Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030" report features an extensive study of the current landscape and future opportunities related to contract services for microbiome therapeutics. The study features an in-depth analysis, highlighting the capabilities of a diverse set of contract service providers, including CMOs and CDMOs. Amongst other elements, the report includes: A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics, including information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, filtration, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of therapeutic (prebiotics and probiotics), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic and anaerobic), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company's contact details. A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise). Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook. An informative, regional capability analysis of microbiome contract manufacturers based on supplier strength (which takes into account a company's size and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities), which provides a means to stakeholders for identifying ways to gain a competitive edge in the industry. A list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account the company's size and its experience in this field), company's pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities. A detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials. An estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world). An informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players. A qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. An analysis of potential market roadmaps and detailed discussion, highlighting various short-term and long-term strategies that can be adopted by microbiome contract manufacturers, in order to expand their respective businesses over the coming years. A review of the varied microbiome-focused initiatives of big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the microbiome therapeutics contract manufacturing market. Based on multiple parameters, such as projected growth of the overall microbiome therapeutics market, cost of goods sold and direct manufacturing costs, we developed informed estimates describing the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of product manufactured (API and FDF), [B] type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), [C] type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), [D] company size (very small / small-sized, mid-sized and large / very large), [E] scale of operation (preclinical, clinical and commercial), and [F] key geographical regions, covering North America, Europe, Asia-Pacific, and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.The opinions and insights presented in this study was influenced by inputs solicited via a survey and discussions held with multiple senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following individuals: Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic) Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals) Assaf Oron (Chief Business Officer, BiomX) Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies) Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories) JP Benya (Vice President, Business Development, Assembly Biosciences) Rob van Dijk (Business Development Manager, Wacker Biotech) Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include: Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts' viewsWhile the focus has been on forecasting the market till 2030, the report also provides our independent view on technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbiome therapeutics contract manufacturing market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to the human microbiome, along with information on the various types of microbiome therapeutics. It also features an elaborate discussion on the functions of the microbiota, emphasizing on the key insights generated from the Human Microbiome Project (HMP). Further, the chapter also includes a description of the various steps that are involved in the manufacturing of microbiome therapeutics. In addition, it highlights the challenges associated with manufacturing such products and the growing need for outsourcing in this domain. Finally, it provides a list of key factors that need to be considered by innovator companies while selecting a CMO partner.

Chapter 4 provides an overview of the microbiome contract manufacturing landscape. It includes information on over 40 contract manufacturers that claim to offer microbiome therapeutics manufacturing services. In addition, it features an in-depth analysis of these companies, based on a number of parameters, such as on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, filtration, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of therapeutic (prebiotics and probiotics), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic, anaerobic, and genetically modified organisms), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company's contact details. A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise).

Chapter 5 includes detailed profiles of key industry players (large and mid-sized companies established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook

Chapter 6 features an informative regional capability analysis of microbiome contract manufacturers based on supplier strength (which takes into account a company's size and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities), which provides a means to stakeholders for identifying ways to gain a competitive edge in the industry.

Chapter 7 features a list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account a company's size and its experience in this field), company's pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities.

Chapter 8 provides a detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials.

Chapter 9 features an estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world).

Chapter 10 features an informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.

Chapter 11 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 12 features an analysis of potential market roadmaps and detailed discussion, highlighting various short-term and long-term strategies that can be adopted by microbiome contract manufacturers, in order to expand their respective businesses over the coming years.

Chapter 13 a review of the varied microbiome-focused initiatives of big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.

Chapter 14 features an elaborate market forecast analysis, highlighting the likely growth of microbiome contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of product manufactured (API and FDF), [B] type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), [C] type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), [D] company size (very small / small-sized, mid-sized and large / very large), [E] scale of operation (preclinical, clinical and commercial), and [F] key geographical regions, covering North America, Europe, Asia-Pacific, and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.Chapter 15 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Gaurav Kaushik (Managing Director and Chief Executive Officer, Meteoric Biopharmaceuticals), Assaf Oron (Chief Business Officer, BiomX), Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies), Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories), JP Benya (Vice President, Business Development, Assembly Biosciences), Rob van Dijk (Business Development Manager, Wacker Biotech), and Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical).

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix, which contains the list of companies and organizations mentioned in the report.

Chapter 19 is an appendix, which contains the list of companies that claim to offer contract manufacturing for probiotic supplements.

Read the full report: https://www.reportlinker.com/p05915359/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read more from the original source:
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms,...

SAN FRANCISCO--(BUSINESS WIRE)--IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of a novel coronavirus disease 2019 (COVID-19), is now a global pandemic. Growing information has demonstrated that a dysregulated and/or hyper-immune response causes a cytokine storm with massive increases in cytokines and chemokines which leads to infiltration of immune cells in multiple organs driving the significant co-morbidity and mortality in severe COVID-19. CCL5/RANTES is a chemokine that binds to the chemokine receptor CCR5. CCR5 is expressed on immune cells such as T-lymphocytes, macrophages, and NK cells. CCL5/RANTES acts like a magnet for these cells expressing CCR5. Thus CCL5/RANTES is a marker for the early stages of immune dysregulation in COVID-19 and as a possible therapeutic marker to determine when and how long therapy targeting CCR5 or RANTES should be continued. Other Cytokines included in the COVID-19 Cytokine Panel can be used to monitor other COVID-19 therapeutic approaches targeting other cytokines involved in the cytokine storm.

Dr. Bruce Patterson, chief executive officer of IncellDx, commented, When we were developing a cytokine quantification assay for possible COVID trials in China, we discovered that infected patients had consistently high levels of CCL5/RANTES in plasma which in some cases was 100 times normal depending on the severity of the disease. Other reports in the literature demonstrated that CCL5/RANTES can be elevated in renal failure, liver failure, coagulopathies, and in Kawasakis disease, all co-morbidities seen in COVID-19. Therapies targeting CCR5 are currently in trials against COVID-19 and we are extremely excited about filing an initial inquiry with the FDA concerning the potential use of a battery of companion tests to monitor the efficacy of drugs in the fight against this virus. It makes sense that we have diagnostics for the presence or absence of virus, exposure to the virus, and the next round of diagnostics should be personalized medicine approaches to determining the efficacy of COVID-19 therapies.

Dr Patterson is the primary author of the pre-print Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19 currently undergoing peer review.

Company files Pre-EUA with FDA for CCR5 receptor occupancy and a COVID cytokine panel including IL-6, IL-8,TNF-a, GM-CSF, and CCL5/RANTES.

Here is the original post:
IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions -...

With the rapid technological breakthrough, personalized medicine is gaining popularity. Personalized medicine is rapidly evolving healthcare, in which the genetic profile of an individual is used to customize health management. Next-Generation Sequencing (NGS) is a state-of-the-art technology that has revolutionized genetic studies. This approach is transforming medicine by providing individuals a genetic profile that guides decisions made regarding the prevention, diagnosis, and treatment of disease; this both maximizes health benefits and minimizes the risk of disease. This technology is becoming more common in oncology, though the clinical benefit of incorporating it into precision medicine strategies remains under significant debate. The speed, accuracy, and increasing affordability of NGS have aided the introduction of precision medicine, which involves designing treatment based on a persons disease-driving molecular alterations. Several studies have shown the utility of NGS in identifying clinically actionable mutations in cancer patients. For example, the Genomics Evidence Neoplasia Information Exchange (GENIE), an international data-sharing consortium, estimated an actionability rate of 30% across numerous cancers. Moreover, rising cancer burden has led to the growth in R&D in this field.

Download Sample of This Strategic Report https://univdatos.com/request_form/form/244

Insights Presented in the Report

Browse Complete Summary of This Report https://univdatos.com/report/next-generation-sequencing-for-personalized-cancer-medicine-market-current-scenario-and-forecast-2020-2026

Reasons to buy this report:

Feel free to contact us for any queries https://univdatos.com/request_form/form/244

Customization Options:

NGS in Personalized Cancer Medicine market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

About Us:

UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. Rigorous secondary and primary research on the market is our USP, hence information presented in our reports is based on facts and realistic assumptions. We have worked with 200+ global clients, including some of the fortune 500 companies. Our clientele praises us for quality of insights, In-depth analysis, custom research abilities and detailed market segmentation.

Contact us:

UnivDatos Market Insights (UMI)

Email: [emailprotected]

Web: https://univdatos.com

Ph: +91 7838604911

Read this article:
Research Report on Next-Generation Sequencing for Personalized Cancer Medicine Market Size & Share 2020 With Top Players and COVID-19 Analysis and...

According toBlueWeave Consultingthe globalAI in Healthcare marketis estimated to reach US$ 37.9 Billion by 2026 with a growing CAGR of 52.3 % during the forecast period 2020- 2026. Several factors driving growth are the increasing need to reduce healthcare costs, rising importance of big data in healthcare, increased acceptance of precision medicine and raising hardware costs. Increasing applicability of AI-based software in medical care and growing investment in venture capital can also be attributed to the surge in demand for this technology. For example, Care Predict, Inc. is using AI technology to track changes in behavioral patterns and activity to predict health issues early.

Request to get the report sample pages at :https://www.blueweaveconsulting.com/ai-in-healthcare-market-bwc19396/report-sample

Increasing number of cross-industry partnerships are expected to boost the healthcare sectors adoption of AI, which is further responsible for its lucrative growth rate. GNS Healthcare entered into a cross-industry partnership with Alliance and Amgen in September 2018 to conduct oncology clinical trials. The goal of the collaboration was to use data from clinical trials and Artificial Intelligence (AI) to identify factors that improve treatment responses in patients with metastatic colorectal cancer (CRC).

AI adoption in healthcare is increasing, with an increased focus on improving patient care quality through the use of artificial intelligence in various aspects of healthcare services, such as virtual assistants & surgeries. The AI-based technologies, such as clinical decision support systems & voice recognition software, help streamline hospital workflow procedures, and optimize medical care, thus improving patient experience. Incorporating AI into healthcare has multiple advantages for both patients and healthcare providers. AI, such as, allows personalized treatment, based on health conditions and past medical history. In addition, AI-based software can be used for continuous health monitoring, which in effect can ensure prompt care & treatment and may ultimately decrease hospital stay. On the other side, medical practitioners unwillingness to adopt new technology, a drastic lack of predetermined and uniform regulatory guidelines, a shortage of curated health care data and data privacy issues impede the markets potential to attain higher grounds.

AI-enabled bots are an AI program that patients can communicate with on a website or by telephone via a chat window. Applications such as scheduling appointments; reviewing insurance coverage parameters; quick access to information on drug interactions and side effects; collecting up-to-date information on patient medications, health care staff and recent procedures; designing special diet strategies for nutritional limited patients; and contacting discharged patients to follow up on treatment plans and ads. Such technologies are expected to lead the growth of hospital and inpatient care systems. Furthermore, the growing need for accurate & early diagnosis of chronic diseases and disorders further supports this markets growth. Nevertheless, the reluctance to implement AI technologies among end-users, lack of trust and potential risks associated with AI in the healthcare sector somewhat restrict the growth of this market.

Application for patient management to see significant growth in the market with significant pace in coming years as successful patient management is one of the most important needs for hospital facilities. Several studies have shown how important patient participation is in improving health outcomes. Lack of such participation contributed greatly to preventable deaths. Smart wearables also play a crucial role in transforming the current healthcare sector. Consumers are also becoming more aware of wearables, and many consumers today believe that wearing a smart device that monitors their vitalities will lead to increased average life expectancy.

Request to get the report description pages at :https://www.blueweaveconsulting.com/ai-in-healthcare-market-bwc19396/

Artificial intelligence in healthcare market is fragmented owing to the presence of number of large-sized companies, mid-sized & small-sized companies, and many start-ups that provide artificial intelligence in healthcare industry. However, the companies that hold the majority share of artificial intelligence in healthcare market are NVIDIA, Intel, IBM, Microsoft, Google, Siemens Healthineer, General Electric (GE) Company, Medtronic, Amazon Web Services (AWS), Koninklijke Philips, Johnson & Johnson Services, Butterfly Network, Welltok, Inc., Micron Technology and Other Prominent Players.

About Us

BlueWeave Consultingis a one-stop solution for market intelligence regarding various products and services online & offline. We offer worldwide market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution. BWC has built its reputation from the scratches by delivering quality performance and nourishing the long-lasting relationships with its clients. We are one of the promising digital market intelligence generation company delivering unique solutions for blooming your business and making the morning, more rising & shining.

Contact Us:

[emailprotected]

https://www.blueweaveconsulting.com

Global Contact: +1 866 658 6826,+1 425 320 4776

Read the original:
AI in Healthcare Market projected a CAGR of 52.3% during the forecast period, 2020-2026 - 3rd Watch News

MANOA A new study out of the University of Hawaii at Manoa suggests reef health may largely be dictated by a microscopic turf war between coral and algae, though other environmental factors still impact reefs, such as ocean acidification or excess nutrients.

The study, published in the journal PNAS, was led by researchers at UH and San Diego State University, and found that the outcome of the competition between coral and turf algae is determined by the assemblage of microbes at the interface where the contenders meet, according to a UH press release.

In the release, researchers explain all plants and animals are associated with communities of viruses and microbes their microbiome that interact via a suite of chemicals produced by their metabolism, termed metabolites.

The study investigated the role of each component, host organisms, viruses, bacteria and metabolites, in coral-turf algal interactions. The researchers gathered data on genes, proteins and metabolic products associated with corals and algae on a reef and directly looked at the bacteria and viruses under a microscope.

We found that when coral interacts with turf algae on a reef, there is a unique chemical and bacterial community that forms at the interface between these two organisms, an emergent microbiome, said Ty Roach, postdoctoral researcher at the Hawaii Institute of Marine Biology in the UH School of Ocean and Earth Science and Technology and co-lead author of the study.

This interface community is made up of larger bacterial cells that use energy at a faster rate. Our data suggest that this change in bacterial size and energy use, which can negatively affect coral, is driven by a change in which types of bacteria dominate the microbiome.

Co-lead author Mark Little, a doctoral candidate at SDSU, explained that chemical analysis indicates the change is driven by bacteria that feed on algal-derived biochemicals, a phenomenon called the algal feeding hypothesis.

Interestingly, these changes in bacterial groups and their energy use, which come from feeding on specific chemicals, are similar to changes seen in the human gut, with dominant bacteria linked to obesity, Little said.

Coral reefs are valued for their cultural and ecological importance, providing protection against storms and waves, and serve as reservoirs of biodiversity. Restoring coral cover and building reef resilience provides the foundation essential to a functional and healthy reef ecosystem, which is critical for the surrounding community.

This highlights the fact that many ecological interactions between organisms are actually mediated by viruses and bacteria, said Forest Rohwer, biology professor at SDSU and senior author of the study. This provides opportunities to engineer probiotics to alleviate the effects of stressors on corals.

The research team plans to use the insight gained from this study to design and test probiotic blends for use on corals. In this way, they aim to utilize personalized-medicine techniques to help corals gain an ecological advantage over competitors such as harmful algae.

Jessica Else, editor-in-chief, can be reached at 245-0457 or jelse@thegardenisland.com.

Read the rest here:
Probiotics for the reef - Thegardenisland.com

Direct to Consumer (DTC) Genetic Testing Market Size was valued around USD 800 million in 2018 and is expected to witness lucrative growth from 2019 to 2025.

Rising adoption of genetic tests in various applications including cancer and various genetic disorders will augment the growth of direct to consumer genetic testing market over the forecast period. Currently developed DTC genetic tests allows customer to recognize chance of acquiring a genetic disease. Thus, growing adoption of DTC genetic testing for premature disease detection and identification of genetic diseases will boost the market growth over forecast timeline. However, the genetic tests are costly which may restrict the genetic testing market over forecast period.

Download the sample report to understand the market growth in Direct to Consume Genetic Testing :

https://www.insidemarketreports.com/sample-request/9/152718/direct-to-consumer-genetic-testing-markets

On the basis of test type the market is segregated into predictive testing, carrier testing, Ancestry & relationship testing, nutrigenomic testing and others. Predictive testing has potential to identify complicated disease which might be associated with the patient in future. Thus predictive testing can help in identifying the diseases ahead of time and suggest personalized medicine which aids to segmental growth of predictive testing market over the future.

Genetic testing market by technology is further divided into Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS). Targeted analysis is used to determine the defect in genes that are responsible for a particular disease. Targeted genotyping can precisely determine a persons genetic pool that encodes vital information regarding various disorders. Targeted analysis is less costly compared to rest of the test which will drive the adoption rate of this segment.

North America is anticipated to account for the largest share of the Global Genetic Testing Market. Increasing innovative technologies in genetic tests coupled with rising adoption of these tests will augment the growth of the market. Asia-Pacific is expected to show rapid growth in coming years. Increasing prevalence of chronic diseases will boost the APAC genetic testing market in forecast period.

By Test type

By Application

By Region

Company Coverage

Questions addressed in the report

Conclusion:

In this report, we had discussed the market situation of Direct to Consume Genetic Testing. As we know the world is going to be tech savvy, the demand of trending products and technologies is also increasing. This report can help to understand the business growth in the Direct to Consume Genetic Testing and new opportunities at new places.

Dont push the river; let the river flow!!

Hurry up! and grab the discount for this report

https://www.insidemarketreports.com/discount/9/152718/direct-to-consumer-genetic-testing-markets

For any type of research report, Contact us at:

Company Name: Inside Market Reports

Address: 1 Apache Way, Westford, Massachusetts 01886, USA

Email: [emailprotected]

Contact no: +1-617-230-0741

Follow this link:
Direct to Consumer (DTC) Genetic Testing Market Analysis, Evolving Opportunities, Industry Trends, Business Growth, Revenue And Forecast upto 2025 -...

Southern Africa is on the receiving end of the devastating impact of climate change, driving millions into hunger.

A record 45 million people mostly women and children in the 16-nation Southern African Development Community are gravely food insecure following repeated drought, widespread flooding and economic disarray, according to the WFP.

Countries like Zambia have been the hardest hit, with 2.3 million people affected as a result of the drought experienced during the 2018/19 growing season. Recently, some parts of the country experienced extensive flooding, which submerged agricultural land.

The magnitude of the problem in this part of the world has reached unprecedented levels, creating a threat to peace, security and stability. At the centre of this catastrophe are the small-scale farmers.

Small-scale farmers in this part of the world are critical because they grow food for household consumption, as well generate income for their local communities.

It is against this backdrop that agricultural biotechnology is gaining support from researchers and small-scale farmers who are struggling to recover from floods and droughts. The most significant advantages of genetically modified (GM) crops to small-scale farmers include environmental protection,boosting food production andsustaining rural livelihoods.

In a telephone interview, Sunday Chileya, a smal-lscale farmer based in the northern part of Zambia, expressed worry over food security as a result of the floods that have wiped out his entire field.

I dont know how I am going to feed my family because everything that I planted has gone, Chileya said.

Chileya, who has some basic knowledge of agricultural biotechnology, said the adoption of the technology was the only solution, owing to recurring floods and droughts that have led to crop failure.

I have an idea of what agricultural biotechnology is and the benefits, so why not promote it to help farmers like me? he asked.

Chileya pointed out that there is need to promote the adoption of the technology if small-scale farmers like him are to continue surviving

The climate keeps changing and so should our ways of farming so that we can survive the effects of climate change, Chileya said.

Experts such as Dr. Kalaluka Munyinda, a University of Zambia (UNZA) lecturer and researcher, say agricultural biotechnology is a significant technology that will help small-scale farmers who have been adversely affected by climate change.

Agricultural biotechnology is safe, he said. We are now experiencing extreme events when it comes to the weather and we can use this technology to develop crop varieties that will withstand any weather pattern.

In order to adapt to and mitigate the devastating impact of climate change, there is a need to encourage the use of agricultural biotechnology, Munyinda said.

We are now experiencing situations where pests and diseases are appearing whether its warm or cold and they are spreading rapidly, Munyinda said.

He emphasized that agricultural biotechnology has significant advantages, contrary to the fears that have been created around the technology.

You see as result of using this technology the use of pesticides harmful to our environment is reduced, Munyinda said, noting that other biotech crops will reduce the use of nitrogen fertilizers that contribute to a rise in greenhouse gases.

He reiterated that small-scale farmers are on the receiving hand of climate change.

Small-scale farmers feed us, he said, adding that 90 percent of the maize we consume is grown by small-scale farmers. So if they get affected we wont eat.

He said the Department of Crop Science at the University of Zambia has been working on maize, finger millet, cowpea and beans using biotechnology and he is hopeful that these will benefit small-scale farmers.

Benedict Tembo, an environmental reporter and editor at the Zambia Daily Mail, said agricultural biotechnology has benefits, contrary to the conspiracies peddled by certain groups with unknown agendas.

Fears that agricultural biotechnology is harmful are totally unfounded, he said. Right now, our region is facing the brunt of climate change and there is need to utilize technology that will help our farmers.

Tembo pointed out that Zambia and some other African countries are missing out on an opportunity to introduce pest-resistant Bt cotton, for example, to fight the pests and diseases that are prevalent in Zambia and other countries across the continent.

Agricultural biotechnology increases productivity, which means small-scale farmers will be able to take care of their families and strengthen their financial capacity, he said.

Tembocalled on journalists, who are on the frontlines in disseminating information to people, to report accurately on the benefits of agricultural biotechnology.

An enlightened journalist is an asset to society, which looks up to him/her for the provision of quality, accurate and timely information on the demystification of myths around biotechnology, he said.

Image: Shutterstock

Read the rest here:
African farmers yearn for biotechnology in the face of climate change - Alliance for Science

"Agricultural Biotechnology Market"

Agricultural Biotechnology Market: Information by Crop Type (Soybean, Maize, Cotton, and others), Application (Herbicide Tolerance, Stacked Traits, Insect Tolerance, and others), Technique (Genetic Engineering, Molecular Breeding, Molecular Diagnostics and Tissue Culture) and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Global Forecast till 2022

Global agricultural biotechnology market, including growth rate, key domains, segmentation, etc

The international agricultural biotechnology market is speculated to witness growth at CAGR of 10.10% by 2022. It was estimated to be worth USD 27,778.64 Million in 2018. Agricultural biotechnology market is considered as one of the swiftly advancing segments due to growing cultivation of biotechnology-based products. The growing level of investment in research and development is also touted as among the prime reasons behind the significant prospect of the market all throughout. With growing entrepreneurial emphasis, the market is speculated to advance in a much effective fashion.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @https://www.marketresearchfuture.com/sample_request/8724

Demand for agricultural biotechnology is witnessing consistent growth. This can be realized through the growing level of cultivation of the biotech crops. Moreover, cultivation has grown all across the globe. In fact, this aspect is speculated to enhance the growth of the international agricultural biotechnology market. It can be seen the level of demand for genetically modified crops has grown in a great way. Especially, the growth has been witnessed in developed parts like Europe.

The international zone for the biotechnology crops was around 190 million hectares, which was 185 million in 2016. In short, the level of cultivation is steadily growing and is expected to remain constant during the forecast period. The amount of land acquired and used for these purposes has grown in all parts, including the US. Above all, more than 70 nations have accepted the biotech crop cultivation. To be specific, India, US, Brazil, Argentina, and Canada are among the leading names in this context.

Agricultural Biotechnology Market Segmentation

International Agricultural Biotechnology Industry can be segmented on the basis of crop Type, Application, And Technique. On the basis of crop type, the global agricultural biotech market can be segmented into soybean, maize, cotton, and others. On the basis of application, the international agricultural biotechnology market is segmented into herbicide tolerance, stacked traits, insect tolerance, and others. In terms of technique, the international agricultural biotechnology is divided into genetic engineering, molecular breeding, molecular diagnostics, and tissue culture. Similarly, the market is segmented on the basis of region as well, is divided into the US, Europe, Asia Pacific, Middle East, and Africa.

Agricultural Biotechnology Market Regional Analysis

On the basis of region, the international agricultural biotech market is segmented into the US, Europe, Asia-Pacific, Middle East, and Africa. The US is considered the global leader in the agricultural biotechnology industry. A consistent boost in the cultivation of biotech crops is said to be the key reason behind the growth.

Asia-Pacific is among the other, a swiftly growing region in the global market. To be specific, the Indian market is the most prominent in this segment. Japan also shows great prospects. UK and Germany are leading European nations. The most significant among others are the African and Middle East market touted to be the most promising.

Agricultural Biotechnology Market Key Players

The Prominent Players in the GlobalAgricultural Biotechnology MarketareArcadia Biosciences (US)., Thermo Fisher Scientific (US), Bayer AG (Germany), Biocentury Transgene Co., Ltd (China), Vilmorin & Cie (France), Eurofins Scientific (Luxembourg), LGC Biosearch Technologies (US), Corteva Agriscience ( US), Dr. Chip Biotech Inc. (Taiwan), Evogene Ltd (Israel), and Yield10 Bioscience, Inc. (US).

Agricultural Biotechnology Industry news

Cole of Duty publishes reports on the global growth perspective of the agricultural biotechnology market. The report figures out all the crucial aspects associated with the market contributing to the market. It also identifies the key domains where the growth prospect is expected to be the most significant. It thus provides wholesome analysis on each aspect associated with the market.

TABLE OF CONTENT1 EXECUTIVE SUMMARY$ 1,350.002 MARKET INTRODUCTION $ 0.003 RESEARCH METHODOLOGY $ 0.004 MARKET DYNAMICS$ 950.005 MARKET FACTOR ANALYSIS$ 950.006 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY CROP TYPE$ 1,650.007 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY APPLICATION$ 1,650.008 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY TECHNIQUE$ 1,650.009 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY REGION

...Continued

LIST OF TABLES$TABLE 1 MARKET SYNOPSIS 13TABLE 2 LIST OF ASSUMPTIONS 15TABLE 3 COUNTRY SCENARIO OF GENETICALLY MODIFIED ORGANISM (GMO) CROPS PROHIBITION 28TABLE 4 GLOBAL AGRICUTURAL BIOTECHNOLOGY MARKET, BY CROP TYPE 2013-2022 (USD MILLION) 35TABLE 5 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, FOR SOYBEAN, BY REGION 2013-2022 (USD MILLION) 35TABLE 6 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, FOR MAIZE, BY REGION 2013-2022 (USD MILLION) 35TABLE 7 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, FOR MEDIUMTHROUGHPUT, BY REGION 2013-2022 (USD MILLION) 36TABLE 8 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, FOR OTHER CROPS, BY REGION 2013-2022 (USD MILLION) 36TABLE 9 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY APPLICATION 2013-2022 (USD MILLION) 38

...Continued

LIST OF FIGURES$FIGURE 1 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET STRUCTURE 15FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 21FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET 24FIGURE 4 GLOBAL AREA OF BIOTECH CROPS, BY REGION, 20152017 (MILLION HECTARES) 25FIGURE 5 CULTIVATION AREA OF BIOTECH CROPS, BY COUNTRY, 2016 & 2017 (MILLION HECTARES) 26FIGURE 6 DRIVERS IMPACT ANALYSIS 27FIGURE 7 RESTRAINT IMPACT ANALYSIS 28FIGURE 8 PORTERS FIVE FORCES ANALYSIS: GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET 30FIGURE 9 VALUE CHAIN ANALYSIS OF THE GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET 32

...Continued

Obtain Premium Research Report Details, Considering the impact of COVID-19 @https://www.marketresearchfuture.com/reports/agricultural-biotechnology-market-8724

About Market Research Future:

AtMarket Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Media ContactCompany Name: Market Research FutureContact Person: Abhishek SawantEmail: Send EmailPhone: +1 646 845 9312Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: PuneState: MaharashtraCountry: IndiaWebsite: http://www.marketresearchfuture.com/reports/agricultural-biotechnology-market-8724

See the rest here:
Coronavirus (COVID-19) Impact on Agricultural Biotechnology Market 2020: Sales, Revenue of Top Companies, Emerging Technology Trends, Future Scope of...

Global Agricultural Biotechnology Market Research Report 20182025 is a historical overview and in-depth study on the current & future market of the Agricultural Biotechnology industry. The report represents a basic overview of the market status, competitor segment with a basic introduction of key vendors, top regions, product types and end industries. This report gives a historical overview of the market trends, growth, revenue, capacity, cost structure, and key drivers analysis.

The report is an exhaustive analysis of this market across the world. It offers an overview of the market including its definition, applications, key drivers, key market players, key segments, and manufacturing technology. In addition, the study presents statistical data on the status of the market and hence is a valuable source of guidance for companies and individuals interested in the industry. Additionally, detailed insights on the company profile, product specifications, capacity, production value, and market shares for key vendors are presented in the report.

Request a sample of this premium research: https://www.bigmarketresearch.com/request-sample/2843408?utm_source=SHASHI&utm_medium=3WN

The total market is further segmented based on company, country, and application/type for competitive landscape analysis. On the contrary, information on industry chain structure, emerging applications, and technological developments in the market makes the report a must-read document.

The report reveals detailed information about the global key players as well as some small players of the Agricultural Biotechnology sector.

Target Audience of the Global Agricultural Biotechnology Market in Market Study:Key Consulting Companies & AdvisorsLarge, medium-sized, and small enterprisesVenture capitalistsValue-Added Resellers (VARs)Third-party knowledge providersInvestment bankersInvestors

These insights help determine the strength of competition and take the necessary steps to obtain a leading position in the Agricultural Biotechnology industry.

Additionally, the research provides a detailed analysis of the key segments of the market with the help of charts and tables. An overview of each market segment such as type, application, and region are also provided in the report. These insights help in understanding the global trends in the Agricultural Biotechnology industry and form strategies to be implemented in the future.

The regional analysis of global Agricultural Biotechnology market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the high disposable income coupled with rising trend of interior designing in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 20182025

Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement. For more connect with us at [emailprotected] or call toll free: +1-800-910-6452

Request a discount on standard prices of this premium research: https://www.bigmarketresearch.com/request-for-discount/2843408?utm_source=SHASHI&utm_medium=3WN

Key Market Segments

The key players profiled in this report includeBayer AG, Dowdupont Inc., Syngenta AG, BASF SE, Adama Agricultural Solutions Ltd., Certis USA LLC, Evogene Ltd., KWS SAAT SE, Monsanto Company, Vilmorin & CIE, and so on.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The study clearly reveals that the Agricultural Biotechnology industry has attained remarkable growth since 20182025. This research report is prepared based on an in-depth analysis of the market by experts. As a final point, stakeholders, investors, product managers, marketing executives, and other professionals seeking unbiased data on supply, demand, and future forecasts would find the report valuable.

Table of Contents

Chapter 1. Global Agricultural Biotechnology Market Definition and ScopeChapter 2. Research MethodologyChapter 3. Executive SummaryChapter 4. Global Agricultural Biotechnology Market DynamicsChapter 5. Agricultural Biotechnology Market, by ComponentChapter 6. Global Agricultural Biotechnology Market, by ServicesChapter 7. Global Agricultural Biotechnology Market, by Organization SizeChapter 8. Agricultural Biotechnology Market, by VerticalChapter 9. Agricultural Biotechnology Market, by Regional AnalysisChapter 10. Competitive Intelligence

About Us:

Big Market Research has a range of research reports from various publishers across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

We are instrumental in providing quantitative and qualitative insights on your area of interest by bringing reports from various publishers at one place to save your time and money. A lot of organizations across the world are gaining profits and great benefits from information gained through reports sourced by us.

Contact us:Mr. Abhishek Paliwal5933 NE Win Sivers Drive, #205, Portland,OR 97220 United StatesDirect: +1-971-202-1575Toll Free: +1-800-910-6452Email [emailprotected]

Read this article:
Agricultural Biotechnology Market Analysis and In-depth Research on Forecast 2018-2025 - 3rd Watch News

Prophecy Market Insights Agriculture Biotechnology market research report focuses on the market structure and various factors affecting the growth of the market. The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Agriculture Biotechnology market over the forecast period (2019-2029).

The data and information required in the market report are taken from various sources such as websites, annual reports of the companies, journals, and others and were validated by the industry experts. The facts and data are represented in the Agriculture Biotechnology report using diagrams, graphs, pie charts, and other clear representations to enhance the visual representation and easy understanding the facts mentioned in the report.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/2913

The Agriculture Biotechnology research study contains 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The predictions mentioned in the market report have been derived using proven research techniques, assumptions and methodologies. This Agriculture Biotechnology market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

All the key players mentioned in the Agriculture Biotechnology market report are elaborated thoroughly based on R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. Also, the report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Agriculture BiotechnologyMarket Key Companies:

Segmentation Overview:

Global agriculture biotechnology market by type:

Global agriculture biotechnology market by application:

Global agriculture biotechnology market by region:

Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis on market segmentation. The report provides an in-depth analysis of the Agriculture Biotechnology market segments. It highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/2913

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Agriculture Biotechnology market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Visit link:
Agriculture Biotechnology Market: Predictable To Witness Sustainable Evolution over 2020-2030 - Cole of Duty

School of Biotechnology

Dublin City University

Dublin City University http://www.dcu.ie is a research-intensive, globally-engaged, dynamic institution that is distinguished both by the quality and impact of its graduates and by its focus on the translation of knowledge into societal and economic benefit. Through its mission to transform lives and societies through education, research and innovation, DCU acts as an agent of social, cultural and economic progress. DCU is Irelands fastest growing university, and now hosts more than 17,000 students across its three academic campuses: DCU Glasnevin Campus, DCU St Patricks Campus and DCU All Hallows campus.

School of Biotechnology

The School of Biotechnology is the academic unit leading life science and biotechnology education and research within the Faculty of Science & Health at Dublin City University (DCU). The school delivers both undergraduate B.Sc and taught M.Sc. postgraduate degree programmes in addition to the education and training of research M.Sc. and Ph.D students under its structured Ph.D programme BioTranslate. It is an active centre of basic, applied and multi-disciplinary research, supporting a defined cluster of intersecting research themes which link closely with the Schools teaching programmes. The School and associated research centres (including the National Institute for Cellular Biotechnology (NICB nicb.ie) and the Water Institute (dcuwater.ie)) offer core facilities and technical support in the areas of Molecular Biology, Bioinformatics, Cell Characterisation, Proteomics, Bioprocessing, Sensor, Analytical Separations and membrane technology. Research projects fall into the general categories of Life Science or Industry-associated with activity in the domains of Health/Ageing/Disease, Biodesign, Environmental Science and Precision Health. They bring together a critical mass of multidisciplinary researchers that are strategically positioned to pursue national and international opportunities for research and innovation. The excellence of the schools research is reflected by funding success from many national and international sources (including direct funds from industry) and the quality of its published and other outputs.

Role Profile

The School is seeking to recruit an Assistant Professor in Biotechnology. The post holder will be expected to contribute to teaching, curriculum development, research, and administrative activities in the School, across all levels. The post holder will also be expected to contribute directly to degree programmes through research-led teaching, student mentoring and supervision of student projects.

Duties and Responsibilities

The duties and responsibilities of this post falls within DCUs Academic Development and Promotions Framework and the principles of the Schools Academic Workload Model with activity across the domains of teaching and learning, research and scholarship, and service and contribution. They are in line with DCUs strategic plan Talent, Discovery and Transformation: 2017-2022.

Teaching and Learning

This post will support the delivery of the Education mission of the University; specifically the delivery of the Schools two core undergraduate programmes, namely the B.Sc in Biotechnology and B.Sc in Genetics & Cell Biology and its substantial contribution to the B.Sc in Analytical Science and B.Sc. in Environmental Science & Technology, in addition to its two taught Masters programmes: M.Sc in Bioprocess Engineering and M.Sc in Diagnostics & Precision Medicine plus our service teaching to support other degree programmes. The School is committed to a flexible mode of module delivery across all of its programmes and the successful candidate(s) will be expected to develop on-line components to their assigned teaching modules. Teaching duties also include the design, supervision and delivery of undergraduate/postgraduate student projects.

Research and Scholarship

In addition to a demonstrable teaching ability, the post holder will be expected to have an independent research profile and the ability to secure grant awards from national/international agencies and/or industry to fund their research activities which would include the recruitment of both postgraduate students and postdoctoral research fellows; contribute to existing School/Centre and DCU-wide research initiatives and expand their network within DCU, nationally and internationally.

Service and Contribution to University

The post holder will be required to undertake administrative roles related to the activities of the School of Biotechnology and the Faculty of Science & Health as assigned by the Head of School. These roles may include but are not limited to the following: Programme Chair; School Executive member; Convenor roles (teaching, research or international), Faculty Management board, Marketing, Safety Committee, Open Days, Conference organisation, Work Placement Tutoring. Participation in courses provided by the University designed to develop skills in such areas as teaching, management and safety will also be expected.

Candidate Requirements

Mandatory Training

The post holder will be required to undertake the following mandatory compliance training: GDPR, Orientation, and Compliance.

Follow this link:
Assistant Professor in Biotechnology job with DUBLIN CITY UNIVERSITY | 210110 - Times Higher Education (THE)

Latest market study on Global Gene Therapy Market Forecast to 2027 Covid-19 Impact and Global Analysis By Cell Type (Somatic Gene Therapy, Germline Gene Therapy); By Application (Genetic Disorder, Cancer, Neurological Disorder, and Others).The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Gene Therapy market during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

Request Sample Copy of Gene Therapy Market at:https://www.theinsightpartners.com/sample/TIPHE100001165/

Gene therapy is the introduction of DNA into a patient to treat a genetic disease or a disorder. The newly inserted DNA contains a correcting gene to correct the effects of a disease, causing mutations. Gene therapy is a promising treatment for genetic diseases and also includes cystic fibrosis and muscular dystrophy. Gene therapy is a suitable treatment for infectious diseases, inherited disease and cancer.

The growth of the gene therapy market is regulated due to various reason which includes the rapid involvement of synthetically modified gene to treat various diseases, it helps in designing the personalized medicine, rise in the research and development of the gene therapy among the others. The gene therapy requires less doses of medicines and is one time treatment, this factor is likely to show growth opportunity for gene therapy market in coming near future.

Some of the key players profiled in the study areSangamo Therapeutics, Inc., bluebird bio, Inc., uniQure N.V., AveXis, Inc., Vineti, Solid Biosciences., Spark Therapeutics, Inc., CHIMERON BIO, RENOVA THERAPEUTICS, HORAMA S.A., etc.

The research provides answers to the following key questions:

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Medical Device, Pharmaceutical, Healthcare and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Gene Therapy Market globally. This report on Gene Therapy Market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Gene Therapy market. The researcher provides an extensive analysis of the Gene Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Gene Therapy industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Scope of the Report

The research on the Gene Therapy market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Gene Therapy market on the basis of end user, product type, application, and demography for the forecast period 20212027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

Gene Therapy Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @https://www.theinsightpartners.com/buy/TIPHE100001165/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

See the original post here:
How Gene Therapy Market: Impact Of COVID-19 On Biotechnology Industry Sangamo Therapeutics, Vineti, Solid Biosciences - Medic Insider

The 60 rating InvestorsObserver gives to Novavax, Inc. (NVAX) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 54 percent of stocks in the Biotechnology industry, NVAXs 60 overall rating means the stock scores better than 60 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 60 would rank higher than 60 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Novavax, Inc. (NVAX) stock has risen 8.4% while the S&P 500 is flat 0% as of 9:51 AM on Friday, Jun 19. NVAX is higher by $4.98 from the previous closing price of $59.27 on volume of 1,092,981 shares. Over the past year the S&P 500 has risen 5.46% while NVAX is higher by 1100.93%. NVAX lost -$4.14 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

The rest is here:
Where Does Novavax, Inc. (NVAX) Stock Fall in the Biotechnology Field? - InvestorsObserver

A rating of 64 puts Sarepta Therapeutics Inc (SRPT) near the middle of the Biotechnology industry according to InvestorsObserver. Sarepta Therapeutics Inc's score of 64 means it scores higher than 64% of stocks in the industry. Sarepta Therapeutics Inc also received an overall rating of 65, putting it above 65% of all stocks. Biotechnology is ranked 11 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Sarepta Therapeutics Inc (SRPT) stock is trading at $167.62 as of 11:39 AM on Friday, Jun 19, an increase of $2.40, or 1.45% from the previous closing price of $165.22. The stock has traded between $165.74 and $168.85 so far today. Volume today is low. So far 200,391 shares have traded compared to average volume of 1,087,373 shares.

To see the top 5 stocks in Biotechnology click here.

Original post:
Is Sarepta Therapeutics Inc (SRPT) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Pharmaceutical & Biotechnology Environmental Monitoring Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market shares, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Sample Report with Latest Industry Trends @ https://healthcareintelligencemarkets.com/request_sample.php?id=27562

Top Key Companies Players Analyzed in this Report are: Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins Sinensis, Lonza, Biomerieux, VAI, Cosasco, RMONI, Amphenol Advanced Sensors, Vaisala

The report analyzes and forecasts the Pharmaceutical & Biotechnology Environmental Monitoring on a and regional level. Pharmaceutical & Biotechnology Environmental Monitoring is highly fragmented and the major players have used various strategies such as new product launches, joint ventures, partnerships, acquisitions, expansions, agreements, and others to increase their footprints in this market.

This report highlights the very profitable Pharmaceutical & Biotechnology Environmental Monitoring Market and its diversity. The report provides a detailed analysis of market segmentation, size and share Market dynamics such as growth drivers, constraints, challenges and opportunities; Service providers, investors, stakeholders and key market participants. The report also highlights the threats that the market will face during the forecast period.

Market segment by Type: Monitoring Equipment, Media, Software, Microbiology Services

Market segment by Application: Pharmaceutical Industry, Biotechnology Industry, Academic & Research Institutes

Get Reasonable Discount on this Premium Report @ https://healthcareintelligencemarkets.com/ask_for_discount.php?id=27562

The Pharmaceutical & Biotechnology Environmental Monitoring Market Report aims to provide a 360-degree view of the market for cutting-edge technologies, key developments, drivers, constraints and future trends by analyzing the impact of these trends on short- and medium-term markets.

Following are the List of Chapter Covers in the Pharmaceutical & Biotechnology Environmental Monitoring Market:

Pharmaceutical & Biotechnology Environmental Monitoring Market OverviewGlobal Economic Impact on IndustryGlobal Market Competition by ManufacturersGlobal Market Analysis by ApplicationMarketing Strategy Analysis, Distributors/TradersMarket Effect Factors AnalysisGlobal Pharmaceutical & Biotechnology Environmental Monitoring Market Forecast

For More Information: https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=27562

*Please contact us for any specific customized requirements or changes you want and we will offer you the report as your requirement.

About Us:

HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare industries. Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.

Contact Us:

Marvella Lit

Address: 90, State Office Center,

90, State Street Suite 700,

Albany, NY 12207

Email: [emailprotected]

Web: http://www.healthcareintelligencemarkets.com

Phone: +44-753-712-1342

See original here:
Pharmaceutical and Biotechnology Environmental Monitoring Market To 2027 Top Leading Vendors like Danaher Corporation, Thermo Fisher Scientific, Merck...

Blue Biotechnology Market Forecast 2020-2026

The Global Blue Biotechnology Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Blue Biotechnology Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://industrygrowthinsights.com/request-sample/?reportId=136719

The Report Covers the Following Companies:Aker BioMarineMarinovaNew England BiolabsPML ApplicationsSea Run HoldingsPICESDonald Danforth Plant Science CenterShell Marine ProductsGeoMarine BiotechnologiesGlycoMarCellgen BiologicalsNurture Aqua TechnologySamudra BiopharmaSanosil Biotech

By Types:EnzymesPharma ProductsBulk ChemicalsBiopolymers

By Applications:Bio-EngineeringGenomicsVaccine DevelopmentDrug DiscoveryOthers

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://industrygrowthinsights.com/ask-for-discount/?reportId=136719

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about Blue Biotechnology Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=136719

About Industrygrowthinsights:Industrygrowthinsights has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://Industrygrowthinsights.com

Continue reading here:
Blue Biotechnology Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026 - Jewish Life News

DUBLIN, June 18, 2020 /PRNewswire/ -- The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.

Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans. This raises the importance of creating public awareness about stem cell research and its clinical potential. The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.

There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US -Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user. Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others. The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period. Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous. The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.

Reasons to Buy:

Key Topics Covered:

1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation1.3.1 Global Stem Cell Therapy Market - By Type1.3.2 Global Stem Cell Therapy Market - By Treatment1.3.3 Global Stem Cell Therapy Market - By Application1.3.4 Global Stem Cell Therapy Market - By End User1.3.5 Global Stem Cell Therapy Market - By Geography

2. Stem Cell Therapy Market - Key Takeaways

3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research

4. Stem Cell Therapy - Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 North America4.2.2 Europe4.2.3 Asia Pacific4.2.4 Middle East & Africa4.2.5 South and Central America4.3 Expert Opinion

5. Stem Cell Therapy Market - Key Market Dynamics5.1 Market Drivers5.1.1 Increasing Awareness Related to the Stem Cells Therapy in Effective Disease Management5.1.2 Growing Demand For Regenerative Medicines5.1.3 Growing Cancer Prevalence Across The Globe5.2 Market Restraints5.2.1 High Cost Related with Stem Cell Therapy5.3 Market Opportunities5.3.1 Growth in the Global Healthcare Market5.4 Future Trends5.4.1 Research Activities and Product Innovations5.5 Impact Analysis

6. Stem Cell Therapy Market - Global Analysis6.1 Global Stem Cell Therapy Market Revenue Forecast And Analysis6.2 Global Stem Cell Therapy Market, By Geography - Forecast And Analysis6.3 Market Positioning of Key Players

7. Global Stem Cell Therapy Market Analysis- by Type7.1 Overview7.2 Stem Cell Therapy Market Revenue Share, by Type (2019 and 2027)7.3 Adult Stem Cell Therapy7.3.1 Overview7.3.2 Adult Stem Cell Therapy : Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.3.3 Hematopoietic Stem Cell Therapy7.3.3.1 Overview7.3.3.2 Hematopoietic Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.3.4 Umbilical Cord Stem Cell Therapy7.3.4.1 Overview7.3.4.2 Umbilical Cord Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.3.5 Neuronal Stem Cell Therapy7.3.5.1 Overview7.3.5.2 Neuronal Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.3.6 Mesenchymal Stem Cell7.3.6.1 Overview7.3.6.2 Mesenchymal Stem Cell: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.4 Induced Pluripotent Stem Cell Therapy7.4.1 Overview7.4.2 Induced Pluripotent Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.4.3 Induced Pluripotent Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.5 Embryonic Stem Cell Therapy7.5.1 Overview7.5.2 Embryonic Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.6 Other Stem Cell Therapy7.6.1 Overview7.6.2 Other Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)

8. Stem Cell Therapy Market Analysis- by Treatment8.1 Overview8.2 Stem Cell Therapy Market, by Treatment 2019 and 2027 (%)8.3 Allogeneic8.3.1 Overview8.3.2 Allogeneic: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)8.4 Autologous8.4.1 Overview8.4.2 Autologous: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)

9. Stem Cell Therapy Market Analysis - by Application9.1 Overview9.2 Stem Cell Therapy Market Revenue Share, by Application (2019 and 2027)9.3 Musculoskeletal9.3.1 Overview9.3.2 Musculoskeletal: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)9.4 Dermatology9.4.1 Overview9.4.2 Dermatology: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)9.5 Cardiology9.5.1 Overview9.5.2 Cardiology: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)9.6 Drug Discovery and Development9.6.1 Overview9.6.2 Drug Discovery and Development: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)9.7 Other Applications9.7.1 Overview9.7.2 Other Applications: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)

10. Stem Cell Therapy Market Analysis- by End User10.1 Overview10.2 Stem Cell Therapy Market, by End User 2019 and 2027 (%)10.3 Academic & Research Institutes10.3.1 Overview10.3.2 Academic & Research Institutes: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)10.4 Hospitals & Specialty Clinics10.4.1 Overview10.4.2 Hospitals & Specialty Clinics : Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)

11. Stem Cell Therapy Market - Geographic Analysis11.1 North America: Stem Cell Therapy Market11.2 Europe: Stem Cell Therapy Market11.3 Asia Pacific: Stem Cell Therapy Market11.4 Middle East & Africa: Stem Cell Therapy Market11.5 South and Central America: Stem Cell Therapy Market

12. Stem Cell Therapy Market -Industry Landscape12.1 Overview12.2 Growth Strategies In The Stem Cell Therapy Market, 2015-201912.3 Organic Growth Strategies12.3.1 Overview12.4 Inorganic Growth Strategies12.4.1 Overview

13. COMPANY PROFILES13.1 MEDIPOST13.1.1 Key Facts13.1.2 Business Description13.1.3 Products and Services13.1.4 Financial Overview13.1.5 SWOT Analysis13.1.6 Key Developments13.2 Pharmicell Co., Inc.13.3 RichSource13.4 BioTime Inc. (Lineage Cell Therapeutics, Inc.)13.5 Mesoblast Limited13.6 Holostem Terapie Avanzate Srl13.7 U.S. Stem Cell, Inc.13.8 Caladrius Biosciences, Inc.13.9 TiGenix NV13.10 AlloSource

For more information about this report visit https://www.researchandmarkets.com/r/m8jwr5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more from the original source:
Worldwide Stem Cell Therapy Industry to 2027 - Growth in the Global Healthcare Market Presents Opportunities - PRNewswire